{
    "clinical_study": {
        "@rank": "18192", 
        "arm_group": [
            {
                "arm_group_label": "DHA Group", 
                "arm_group_type": "Experimental", 
                "description": "DHA Group will receive 75 milligrams of docosahexaenoic acid (DHA) per kilogram of their baseline weight.\nThey will receive one dose, administered by enteral feeding every 24 h during 14 days"
            }, 
            {
                "arm_group_label": "Control Group (Placebo)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Control group will receive sunflower oil which is the excipient of the DHA in this study.\nThey will receive one dose every 24 h during 14 days."
            }
        ], 
        "brief_summary": {
            "textblock": "-  The purpose of this study is to determine whether docosahexaenoic acid are effective in\n           the prevention or reducing severity of necrotizing enterocolitis (NEC) in preterm\n           neonates < 1500 g at birth who are starting enteral feeding.\n\n        -  if NEC is prevented, this study will measure whether hospital stay is also reduced in\n           neonates who receive Docosahexaenoic acid (DHA)"
        }, 
        "brief_title": "Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Necrotizing Enterocolitis", 
        "condition_browse": {
            "mesh_term": [
                "Enterocolitis", 
                "Enterocolitis, Necrotizing"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  Preterm neonates with birth weight less than 1500 g are in higher risk to develop NEC.\n\n        -  NEC is an inflammatory condition that:\n\n             1. Is the medical urgency most frequent of gastrointestinal tube that requires\n                neonatal intensive care\n\n             2. may perforate infant\u00b4s bowel requiring surgery from 20% to 60% of the cases\n\n             3. may cause infant's death  in 20% to 42% of the cases.\n\n             4. has no adequate treatment worldwide, therefore prevention is needed\n\n        -  DHA by enteral feeding has been administrated by our research group to attenuate\n           inflammatory response in septic and surgical neonates.\n\n        -  Our results showed:\n\n             1. lower Interleukin(IL)-1 beta in septic neonates, but in surgical they also showed\n                less IL-6 and anti-inflammatory cytokines IL-10 and IL-1ra, after confounder\n                adjustment\n\n             2. increased weight, length and fat mass gain in septic neonates\n\n             3. decreased organic failures in surgical neonates, and\n\n             4. lower stay at neonatal intensive care in surgical neonates\n\n      DHA has not been used as unique intervention at a high but physiological dose; in addition,\n      our previous results found an anti-inflammatory effect in neonates.Therefore, we expect that\n      preterm infants may have a reduced bowel inflammatory response and lower NEC events and or\n      severity"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Birth weight lower than 1500 g\n\n          -  Adequate weight for gestational age\n\n          -  Clinically stable to begin enteral feeding\n\n          -  Written informed consent by both parents\n\n        Exclusion Criteria:\n\n          -  Clinical and biochemical data of inflammatory response such as body core temperature\n             altered, cardiac and respiratory frequency low or high according to age, leucocytosis\n             or leucopenia, taking into account the thresholds reported by Goldstein in Pediatric\n             Critical Care Medicine 2005 Vol 6 N\u00b01.\n\n          -  Persistent bleeding at any level\n\n          -  Mother taking n-3 supplements and planning to breastfed\n\n          -  Parents who decline the authorization for participating in the study\n\n          -  Early discharge to other hospital outside the metropolitan area\n\n          -  Persistent vomiting\n\n          -  Receiving medication to avoid coagulation\n\n          -  Gastrointestinal malformations"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "2 Weeks", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "306", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 23, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745510", 
            "org_study_id": "DHA-ECN", 
            "secondary_id": "DHA, ECN and Preterm"
        }, 
        "intervention": [
            {
                "arm_group_label": "DHA Group", 
                "description": "Docosahexaenoic acid from algae source", 
                "intervention_name": "Docosahexaenoic acid (DHA)", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "n-3 Fatty Acids"
            }, 
            {
                "arm_group_label": "Control Group (Placebo)", 
                "description": "Placebo was designed to mimic the color and consistence of the oil that contains DHA", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Sunflower oil, Placebo for DHA intervention"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "docosahexaenoic acid", 
            "n-3 fatty acids", 
            "necrotizing enterocolitis", 
            "preterm infants"
        ], 
        "lastchanged_date": "March 11, 2013", 
        "location": {
            "contact": {
                "email": "mariela_bernabe@yahoo.com", 
                "last_name": "Mariela Bernabe-Garcia, PhD", 
                "phone": "+52 55 56276944"
            }, 
            "contact_backup": {
                "email": "marsau2@prodigy.net.mx", 
                "last_name": "Mardia Lopez-Alarcon, PhD", 
                "phone": "+ 52 55 56276944"
            }, 
            "facility": {
                "address": {
                    "city": "Mexico City", 
                    "country": "Mexico", 
                    "state": "Distrito Federal", 
                    "zip": "06720"
                }, 
                "name": "Unit of Medical Research in Nutrition, Pediatric Hospital, IMSS"
            }, 
            "investigator": [
                {
                    "last_name": "Leovigildo Mateos, MSc", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mardia Lopez-Alarcon, PhD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Mariela Bernabe-Garcia, PhD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy of Enteral Administration of the Docosahexaenoic Acid on Necrotizing Enterocolitis, Cytokines and Hospital Stay in Preterm Neonates", 
        "overall_contact": {
            "last_name": "Mariela Bernabe-Garcia, PhD", 
            "phone": "+52 55 56276944"
        }, 
        "overall_contact_backup": {
            "email": "marsau2@prodigy.net.mx", 
            "last_name": "Mardia Lopez-Alarcon, PhD", 
            "phone": "+ 52 55 56276944"
        }, 
        "overall_official": {
            "affiliation": "Instituto Mexicano del Seguro Social", 
            "last_name": "Mariela Bernabe-Garcia, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Mexico: Coordinaci\u00f3n de Investigaci\u00f3n en Salud", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Neonates will receive enteral DHA at beginning of their first enteral feeding and NEC will be diagnosed during hospital stay, measured as presence or absence, as well as severity of NEC by Bell's score.", 
            "measure": "Necrotizing enterocolitis (NEC)", 
            "safety_issue": "No", 
            "time_frame": "Patients will be followed for the duration of hospital stay, an expected average of 6 weeks"
        }, 
        "reference": [
            {
                "PMID": "16750345", 
                "citation": "L\u00f3pez-Alarc\u00f3n M, Bernabe-Garc\u00eda M, Del Prado M, Rivera D, Ruiz G, Maldonado J, Villegas R. Docosahexaenoic acid administered in the acute phase protects the nutritional status of septic neonates. Nutrition. 2006 Jul-Aug;22(7-8):731-7. Epub 2006 Jun 5."
            }, 
            {
                "PMID": "22079797", 
                "citation": "L\u00f3pez-Alarc\u00f3n M, Bernabe-Garc\u00eda M, del Valle O, Gonz\u00e1lez-Moreno G, Mart\u00ednez-Basilea A, Villegas R. Oral administration of docosahexaenoic acid attenuates interleukin-1\u03b2 response and clinical course of septic neonates. Nutrition. 2012 Apr;28(4):384-90. doi: 10.1016/j.nut.2011.07.016. Epub 2011 Nov 12."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745510"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Coordinaci\u00f3n de Investigaci\u00f3n en Salud, Mexico", 
            "investigator_full_name": "Mariela Bernabe Garc\u00eda", 
            "investigator_title": "Principal investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Plasma cytokines will be determined before to the beginning of the enteral feeding  (baseline), at day 3, and at day 14, of the beginning with enteral feeding. Cytokines will be measured by a multiplex kit in picograms/mL.", 
                "measure": "Cytokines Interleukin (IL)-1 beta, Tumoral necrosis factor (TNF)-alpha, IL-6, IL-10", 
                "safety_issue": "No", 
                "time_frame": "At baseline, at day 3, and at day 14"
            }, 
            {
                "description": "Hospital stay includes intensive stay care and preterm service (where clinically stable babies are attended) until they are discharged from the hospital to home, in days.", 
                "measure": "Hospital stay", 
                "safety_issue": "No", 
                "time_frame": "The duration of hospital stay, an expected average of 6 weeks"
            }
        ], 
        "source": "Coordinaci\u00f3n de Investigaci\u00f3n en Salud, Mexico", 
        "sponsors": {
            "collaborator": {
                "agency": "National Council of Science and Technology, Mexico", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Coordinaci\u00f3n de Investigaci\u00f3n en Salud, Mexico", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}